Abiopharma

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Calidi Biotherapeutics - Calidi Biotherapeutics Announces Shareholder Letter from CEO

New Form SC TO-C - Turnstone Biologics Corp. Filed: 2025-06-27 AccNo: 0001193125-25-149747 Size: 49 KB

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Schrödinger, Inc. - Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/RefractoryWaldenström Macroglobulinemia

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Calidi Biotherapeutics Announces Shareholder Letter from CEO

CorMedix Inc. Announces Pricing of Public Offering of Common Stock

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

UTHR: Notification

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

New Form 8-K - Bausch & Lomb Corp Filed: 2025-06-27 AccNo: 0001193125-25-149726 Size: 4 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements …

New Form 8-K - UNITED THERAPEUTICS Corp Filed: 2025-06-27 AccNo: 0001104659-25-063287 Size: 372 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and …